any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

Please amend the application as follows:

In the Specification:

In the specification at page 1, please delete the paragraph appearing at lines 4-11 (the Cross-Reference section), and substitute therefor the following paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. Application No. 09/296,281, filed April 22, 1999, which is a divisional of U.S. Application No. 09/177,387, filed October 23, 1998, which claims the benefit of the filing date of U.S. Provisional Application No. 60/065,930, filed October 24, 1997, the disclosures of which are incorporated by reference herein in their entireties.

In the specification at page 2, please delete the paragraph appearing at lines 16-18.

In the specification at page 70, please delete the partial paragraph appearing at lines 36-41 and substitute therefor the following partial paragraph:

Part V: Expression of Fusion Proteins

Two colonies from each transformation were picked into 2 ml of rich medium (CIRCLEGROW® brand culture medium, Bio101 Inc.) in 17 × 100 mm plastic tubes (FALCON® brand plasticware, Cat. No. 2059, Becton Dickinson) containing 100 μg/ml ampicillin and shaken vigorously for about 4 hours at 37°C, at which time the cultures were visibly turbid. One ml of each culture was transferred to a new tube containing 10 μl of 10% (w/v) IPTG

In the specification at page 77, please delete the paragraph appearing at lines 7-17, and substitute therefor the following paragraph:

Twelve of the 26 small colonies were grown overnight in rich broth (CIRCLEGROW® brand culture medium) that contained 25 μg/ml kanamycin, and miniprep DNAs were prepared from these cultures. All twelve miniprep plasmids were about 8 kb in size, which corresponded to the size expected for replacement of the choramphenicol resistance and tet repressor genes in pEZC1202 with the 5.2 kb PCR product. The predicted recombinant product is shown in Figure 9C. Two of these plasmids were cut with AvaI (8 sites predicted) and BamHI (4 sites predicted). All the predicted AvaI fragments appeared to be present. One of the BamH I sites predicted in the PCR product (the one closest to the attB end) was absent from both minipreps, but the other BamHI fragments were consistent with the expected structure of the cloned 5.2 kb PCR product.